Loading stock…

Taysha Gene Therapies, Inc. (TSHA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Taysha Gene Therapies, Inc.

TSHAMarket cap $1.44BPrice $4.4

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops gene therapies for rare, often fatal genetic diseases affecting the central nervous system, including Rett syndrome and GAN. Its lead candidate targets a childhood disorder with no approved treatment, betting one-time gene fixes can replace a lifetime of care.

In Bastion Portfolios?

52W Return-6%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+57%10

Revenue Forecast

Rev CAGR (1y)+13%7

Rev CAGR (3y)+134%10

Rev CAGR (5y)+153%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-2792%1

Net Income Margin-2728%1

Free Cash Flow Margin-2417%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-47%1

ROA-37%1

Earnings Stabilityna–

GEAR+VERY WEAK7

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV3.74

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-9.2%1

Dividend Yieldna–

Momentum

Short term

1 month return-19%1

3 month return-32%1

YTD return-19%2

Mid term

Price vs 52wHigh61%2

1 year return-12%3

Long term

3 year return+65%6

5 year return-76%1

Risk Shield

Price Risk

Beta2.71

Volatility70%1

Free Cash Flow

Free Cash Flow Margin-2417%1

Free Cash Flow Yield-9.2%1

Quality

ROCE-41%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

TSHATaysha Gene Therapies

Revenue FY25$10M

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+57%10

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+134%10

Revenue, next 5Y, CAGR+153%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 57%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 134%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 57%/yr over the last 3 years and is set to grow 134%/yr from here.

The runway holds up: revenue is set to grow 153%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK7 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-19%1

3-month return-32%1

YTD return-19%2

MID & LONG-TERM▾SCORE

% of 52-week high61%2

1-year return-12%3

3-year return+65%6

5-year return-76%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+65% over three years and -76% over five), behind 60% of the market.

It's down 12% over the past year, now 39% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-19%), over three months (-32%) and so far this year (-19%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Taysha Gene Therapies, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TSHATaysha Gene Therapies

Revenue FY25$10M

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+57%10

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+134%10

Revenue, next 5Y, CAGR+153%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 57%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 134%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 57%/yr over the last 3 years and is set to grow 134%/yr from here.

The runway holds up: revenue is set to grow 153%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK7 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-19%1

3-month return-32%1

YTD return-19%2

MID & LONG-TERM▾SCORE

% of 52-week high61%2

1-year return-12%3

3-year return+65%6

5-year return-76%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+65% over three years and -76% over five), behind 60% of the market.

It's down 12% over the past year, now 39% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-19%), over three months (-32%) and so far this year (-19%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Taysha Gene Therapies, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community